Dr Robert Alexander Joins T3D Therapeutics’ Scientific Advisory Board

T3D Therapeutics, Inc., a clinical-stage drug development company engaged in the development of a new orally administered treatment for Alzheimer’s disease (AD), today announced that Dr. Robert Alexander has joined the Company’s Scientific Advisory Board.

CEO John Didsbury states,

“As we advance the clinical development of our drug candidate, T3D-959, beyond our completed Phase 2 PIONEER trial, Dr. Alexander’s expertise in Alzheimer’s drug development and regulatory affairs will be invaluable.”

Dr Robert Alexander is currently the Chief Scientific Officer of the Alzheimer’s Prevention Initiative at the Banner Alzheimer’s Institute and a Research Professor in the Department of Psychiatry at the University of Arizona School of Medicine-Phoenix. Previously, he held positions as VP in the neuroscience therapeutic area unit at Takeda, VP and head of clinical for the neuroscience and pain at Pfizer, VP of clinical for CNS and the pain innovative medicines unit (iMed) at AstraZeneca, as well as other positions in discovery medicine and neuroscience at GSK and Merck. Dr. Alexander received his M.D. degree from The University of Chicago Pritzker School of Medicine. He is certified by the American Board of Psychiatry and Neurology and specializes in psychopharmacology, having conducted or supervised clinical studies in a broad range of neurologic and psychiatric indications.

“The Phase 2 results of T3D-959 in mild-to-moderate AD patients are compelling and offer the strong potential to have a positive impact on this catastrophic disease. I am looking forward to assisting the Company to help advance this drug to market as expeditiously as possible,” said Dr. Alexander.

About T3D-959: T3D-959, a small molecule, delivered orally once daily, is a brain-penetrating PPAR delta/gamma dual nuclear receptor agonist designed to improve both glucose and lipid metabolism dysfunctions present in AD and other neurodegenerative disorders.

Hot this week

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMedâ„¢ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.